Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis
Authors' conclusion
In conclusion, this meta-analysis proves that SGLT2i significantly reduce the 24-hour ambulatory BP. SGLT2i may be considered an effective treatment option for lowering the BP in addition to standard care in patients with hypertension and type 2 DM.
Study context
- Population
- Patients with T2D and hypertension; RCTs published until May 31, 2023 (PubMed, Google Scholar, Cochrane)10 RCTs
- Comparison
- SGLT2i vs placebo or standard care
- Outcome
- 24-hour ambulatory systolic BP (SBP) and diastolic BP (DBP)
Pooled result
As reported in the abstract
24-hour ambulatory BP
Weighted MD, 24-h ambulatory systolic BP (SBP)
−5.08 mm Hg
95% CI −7.02 to −3.14P < 0.00001
I2 = 83%
Weighted MD, 24-h ambulatory diastolic BP (DBP)
−2.73 mm Hg
95% CI −4.25 to −1.20P = 0.0005
I2 = 91%
Further pooled results
Sensitivity analysis
- Excluding specific studies reduced heterogeneity while maintaining statistically significant and clinically relevant blood pressure (BP) reductions
Original publication
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis. Endocr Pract. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →